Guangzhou Aisima Bio-pharmaceutical Technology

Guangzhou ExcelMab Bio-pharmaceutical Technology (ExcelMab) is a clinical-stage biopharmaceutical company specializing in the development of next-generation bispecific antibody (BsAb) therapeutics for cancer immunotherapy. The company utilizes its proprietary ExMab® platform, which employs structure-based protein engineering to create stable, low-immunogenicity bispecific molecules with high heterodimer expression rates. ExcelMab's lead programs include EX103, a CD20xCD3 bispecific antibody for B-cell non-Hodgkin lymphoma, and EX101, a HER2xCD3 bispecific antibody for HER2-positive solid tumors. Recognized as a leader in the Chinese bispecific antibody space, the company aims to provide safer and more effective treatment options for patients who have failed standard therapies.